How to Test for Hypothyroidism: A Clear Guide to Thyroid Labs

Why TSH Is the First Test Ordered

TSH, or thyroid-stimulating hormone, is secreted by the pituitary gland and rises when thyroid hormone output is insufficient. Because the pituitary amplifies even tiny drops in circulating T4, TSH changes before Free T4 moves outside its reference range. This sensitivity makes TSH the most cost-effective single marker for detecting early thyroid dysfunction. A 2013 systematic review in the Annals of Internal Medicine confirmed TSH as the preferred first-line test for thyroid screening in outpatient settings.

How TSH Is Measured

TSH is a simple blood draw. No fasting is required, though specimens collected between 8 a.m. And noon reflect the diurnal TSH peak and produce the most reproducible results. The FDA-cleared immunoassay platforms used in most US clinical laboratories achieve functional sensitivity below 0.01 mIU/L, meaning third-generation assays can distinguish suppressed TSH from low-normal TSH reliably.

What a High TSH Means

A TSH above the upper reference limit (typically 4.0 to 4.5 mIU/L depending on the laboratory) indicates the pituitary is working harder to stimulate an underperforming thyroid. The diagnosis is not made from a single result. ATA guidelines recommend confirming any elevated TSH with a repeat measurement 2 to 3 months later because transient TSH elevation occurs during recovery from non-thyroidal illness, after iodine load, and during certain medication changes.

TSH Alone Is Not Always Enough

TSH can be misleading in central hypothyroidism (pituitary failure), during the first trimester of pregnancy, and in patients taking biotin supplements above 5 mg/day. Biotin at high doses interferes with streptavidin-biotin immunoassay platforms and can falsely suppress TSH readings, producing a picture that mimics hyperthyroidism. Patients should stop biotin for at least 48 hours before any thyroid panel.

Free T4: The Confirmatory Test

Once TSH is elevated, Free T4 (FT4) tells the clinician whether the thyroid deficiency is subclinical or overt. Free T4 measures only the unbound, biologically active fraction of thyroxine, unlike total T4, which includes protein-bound hormone and varies with pregnancy, oral contraceptive use, and liver disease.

Reference Range and Clinical Interpretation

Most laboratories set the Free T4 reference interval at 0.8 to 1.8 ng/dL (10 to 23 pmol/L), though inter-laboratory variation exists. A 2019 analysis published in Thyroid (N=8,946) found that Free T4 reference intervals differ by up to 30% across assay platforms, which means a result cannot be interpreted without knowing the specific assay used.

• TSH elevated, Free T4 normal: subclinical hypothyroidism
• TSH elevated, Free T4 low: overt hypothyroidism requiring treatment
• TSH normal or low, Free T4 low: suspect central (secondary) hypothyroidism; pituitary MRI warranted

Subclinical Hypothyroidism: When to Treat

The TRUST trial (N=737, published in JAMA 2017) randomized adults aged 65 and older with subclinical hypothyroidism (median TSH 6.4 mIU/L) to levothyroxine or placebo. Treatment produced no significant improvement in hypothyroid symptoms or quality of life at 1 year, suggesting that automatic treatment of mild subclinical hypothyroidism in older adults is not supported by evidence. For patients under 65 with TSH persistently above 10 mIU/L or with symptoms and positive TPO antibodies, treatment is generally recommended per ATA guidance.

Free T3: When and Why to Add It

Free T3 (FT3) measures the active form of thyroid hormone that binds nuclear receptors in peripheral tissues. The thyroid secretes roughly 20% of circulating T3 directly; the remaining 80% comes from peripheral conversion of T4 by deiodinase enzymes. Because most T3 is derived from conversion, Free T3 is not useful for initial diagnosis of hypothyroidism in most patients.

Situations Where Free T3 Adds Clinical Value

Free T3 becomes relevant in three specific scenarios:

1. A patient remains symptomatic (fatigue, cognitive slowing, cold intolerance) despite a normal TSH on levothyroxine monotherapy.
2. Evaluation of T4-to-T3 conversion issues, as seen in patients with a DIO2 polymorphism (Thr92Ala variant), which reduces peripheral deiodinase-2 activity. A 2019 study in Thyroid (N=1,100) found that patients carrying the DIO2 Thr92Ala polymorphism reported worse psychological well-being on T4 monotherapy compared to non-carriers.
3. Monitoring combination levothyroxine plus liothyronine (T3) therapy to avoid T3 toxicity.

Free T3 Is Not a Diagnostic Screen

The American Thyroid Association's 2014 hypothyroidism guidelines explicitly state that Free T3 measurement is not recommended for the routine diagnosis of hypothyroidism. Isolated low Free T3 with normal TSH and Free T4 most often reflects non-thyroidal illness (euthyroid sick syndrome) rather than primary thyroid failure.

Thyroid Antibody Tests

Antibody panels identify autoimmune thyroid disease as the mechanism driving hypothyroidism. This matters clinically because Hashimoto's thyroiditis progresses to overt hypothyroidism at a rate of approximately 4 to 5% per year in antibody-positive patients with subclinical TSH elevation. A longitudinal study published in the Journal of Clinical Endocrinology and Metabolism (N=2,779, follow-up 20 years) found that TPO antibody positivity was the strongest independent predictor of progression from subclinical to overt hypothyroidism.

TPO Antibodies (Anti-TPO)

Thyroid peroxidase antibodies are present in approximately 95% of patients with Hashimoto's thyroiditis and in 60 to 75% of those with Graves' disease. A positive TPO result (generally above 35 IU/mL, though thresholds vary by laboratory) in a patient with an elevated TSH confirms autoimmune thyroiditis as the etiology. Titer height does not correlate well with disease severity and should not be used to monitor treatment response.

Thyroglobulin Antibodies (Anti-Tg)

Anti-thyroglobulin antibodies appear in roughly 60 to 70% of Hashimoto's patients. They are primarily used alongside thyroglobulin measurement in thyroid cancer surveillance. In the context of hypothyroidism diagnosis, anti-Tg testing adds value only when anti-TPO is negative but clinical suspicion for autoimmune disease remains high. The 2015 ATA differentiated thyroid cancer guidelines describe anti-Tg as an essential co-analyte whenever serum thyroglobulin is measured post-thyroidectomy.

TSH Receptor Antibodies (TRAb) in the Hypothyroid Workup

TRAb, including thyroid-stimulating immunoglobulins (TSI), are primarily markers of Graves' disease. They appear in the hypothyroidism workup when a patient presents with a fluctuating TSH pattern or a history alternating between hypo- and hyperthyroid states, which can represent the burnt-out phase of Graves' disease.

Total T4 and Total T3: Mostly Obsolete

Total T4 and total T3 measure both bound and free hormone fractions. Because binding proteins (thyroxine-binding globulin, albumin, transthyretin) fluctuate with pregnancy, malnutrition, cirrhosis, and medication use, total hormone levels are unreliable for thyroid function assessment. The National Academy of Clinical Biochemistry's laboratory medicine practice guidelines state that free hormone measurements have replaced total measurements for routine thyroid evaluation. Total T3 remains useful only in the diagnosis of T3-toxicosis (a form of hyperthyroidism) and is not part of a standard hypothyroidism panel.

Reverse T3: What the Evidence Actually Shows

Reverse T3 (rT3) is a biologically inactive isomer of T3 produced when T4 is converted by deiodinase-3 rather than deiodinase-2. Its serum level rises during physiological stress, caloric restriction, major surgery, sepsis, and amiodarone therapy. Proponents of rT3 testing argue that elevated rT3 can cause "cellular hypothyroidism" even with normal TSH and Free T4.

This claim lacks controlled clinical trial support. A 2013 review in the Journal of Clinical Endocrinology and Metabolism found no validated clinical outcome tied to elevated reverse T3 in the absence of non-thyroidal illness. The ATA does not recommend routine reverse T3 testing in its hypothyroidism guidelines, and insurance coverage for the test is inconsistent precisely because diagnostic utility is unproven. Order rT3 only in the specific context of evaluating non-thyroidal illness severity or amiodarone-related thyroid dysfunction.

Thyroid Ultrasound: Imaging as an Adjunct to Labs

Thyroid ultrasound does not diagnose hypothyroidism biochemically, but it identifies structural changes that corroborate Hashimoto's thyroiditis. A heterogeneous, hypoechoic gland with reduced volume on ultrasound is characteristic of autoimmune thyroiditis and is often seen even when antibody titers are borderline. A 2017 study in Thyroid (N=4,649) found that ultrasound-detected thyroid heterogeneity had a sensitivity of 82% and specificity of 90% for Hashimoto's thyroiditis when used alongside TPO antibody testing.

Ultrasound is indicated when:

• A nodule is palpated or suspected
• TSH remains elevated despite negative antibodies
• The gland feels enlarged or asymmetric on physical exam
• Thyroid cancer surveillance is part of the clinical picture

Ultrasound does not replace biochemical testing and should not be ordered as a first-line step in suspected hypothyroidism without lab results already in hand.

Hypothyroidism in Special Populations

Pregnancy

Thyroid hormone requirements increase by approximately 25 to 50% during pregnancy because of rising thyroxine-binding globulin, placental transfer of T4 to the fetus, and increased renal iodine clearance. The 2017 ATA guidelines on thyroid disease in pregnancy define trimester-specific TSH targets: <2.5 mIU/L in the first trimester and <3.0 mIU/L in the second and third trimesters. TSH should be checked at the first prenatal visit in all women with known hypothyroidism or positive TPO antibodies.

Older Adults

TSH reference ranges shift upward with age. A TSH of 5.5 mIU/L in an 80-year-old may be age-appropriate rather than pathological. Data from NHANES III showed that the 97.5th percentile TSH in adults over 80 years old was 7.49 mIU/L compared to 4.12 mIU/L in adults aged 20 to 29, supporting the use of age-adjusted reference intervals rather than a single universal cutoff.

Central Hypothyroidism

Central (secondary) hypothyroidism results from pituitary or hypothalamic failure. TSH is normal or low despite inadequate thyroid hormone output. Free T4 drives diagnosis in this population. A 2018 European Thyroid Journal consensus statement on central hypothyroidism recommends Free T4 as the primary diagnostic and monitoring marker when pituitary disease is suspected, with TSH used only as a secondary check.

Interpreting a Complete Thyroid Panel: A Practical Framework

The table below summarizes the most common laboratory patterns and their clinical interpretation:

| TSH | Free T4 | Free T3 | TPO Ab | Interpretation | |---|---|---|---|---| | High | Low | Low or normal | Positive | Overt Hashimoto's hypothyroidism | | High | Normal | Normal | Positive | Subclinical autoimmune hypothyroidism | | High | Normal | Normal | Negative | Subclinical hypothyroidism, non-autoimmune | | Normal | Low | Low | Any | Central (secondary) hypothyroidism | | Normal | Normal | Low | Negative | Non-thyroidal illness; euthyroid sick syndrome | | Normal | Normal | Normal | Positive | Euthyroid Hashimoto's (monitor annually) | | Low | Low or normal | Any | Any | Suspect pituitary pathology or exogenous T4 excess |

No single pattern is pathognomonic. Lab results must be interpreted alongside symptoms, medication history, and prior TSH trajectory.

How Often Should Thyroid Labs Be Rechecked?

Frequency depends on clinical status:

• Newly abnormal TSH, not yet on treatment: Repeat TSH and Free T4 in 2 to 3 months. A single elevated TSH does not justify lifelong medication.
• Stable on levothyroxine: Recheck TSH every 6 to 12 months once the dose is optimized. The ATA recommends TSH measurement 4 to 8 weeks after any levothyroxine dose change, as steady-state takes approximately 6 weeks.
• Pregnancy: TSH every 4 weeks through the first 20 weeks of gestation, then once at 30 weeks.
• Positive TPO antibodies, normal TSH: Annual TSH monitoring per ATA guidance, given the 4 to 5% annual progression risk.
• Post-thyroidectomy: TSH every 6 to 12 months depending on whether the indication was benign or malignant disease.

A 2014 Cochrane review on monitoring intervals for treated hypothyroidism found insufficient evidence to specify an optimal interval but noted that annual TSH monitoring in stable patients was consistent with most international guidelines.

Medications That Alter Thyroid Lab Results

Several common drugs shift thyroid lab values without reflecting true thyroid disease:

• Biotin (>5 mg/day): Falsely lowers TSH and raises Free T4 via assay interference. The FDA issued a safety communication in 2017 warning clinicians about biotin interference in thyroid immunoassays.
• Amiodarone: Raises TSH transiently at initiation; can also cause overt hypothyroidism or hyperthyroidism with prolonged use. A 2018 study in the Journal of Clinical Endocrinology and Metabolism found thyroid dysfunction in 14 to 18% of amiodarone-treated patients.
• Lithium: Inhibits thyroid hormone synthesis and secretion; hypothyroidism develops in up to 40% of long-term users. A systematic review in BMJ Open (2022) found a pooled hypothyroidism incidence of 6.3 per 100 person-years in lithium-treated psychiatric patients.
• Glucocorticoids (high-dose): Suppress TSH secretion, potentially masking hypothyroidism during steroid tapers.
• Calcium carbonate and iron supplements: Reduce levothyroxine absorption by up to 40% when taken simultaneously; administer levothyroxine at least 4 hours apart from these agents.

Ordering Thyroid Labs: A Step-by-Step Clinical Protocol

For most outpatient scenarios, a tiered approach produces accurate diagnoses while minimizing unnecessary testing costs:

Step 1. Order TSH alone as the initial screen. Cost is low (<$30 at most reference labs) and sensitivity for primary hypothyroidism exceeds 99%.

Step 2. If TSH is above the upper reference limit, add Free T4 from the same or next blood draw to classify overt versus subclinical disease.

Step 3. Add TPO antibodies if TSH remains elevated on repeat testing, especially if the patient has a personal or family history of autoimmune disease, type 1 diabetes, or celiac disease. The American Association of Clinical Endocrinology recommends TPO antibody testing to identify patients at highest risk of progression from subclinical to overt hypothyroidism.

Step 4. Add Free T3 only if the patient has persistent symptoms despite normalized TSH on levothyroxine, or if T3 toxicosis needs to be excluded.

Step 5. Consider thyroid ultrasound if a structural abnormality is suspected or antibody results are discordant with clinical presentation.

According to CDC data, hypothyroidism affects approximately 4.6% of the US population aged 12 and older when subclinical cases are included, making systematic and accurate lab interpretation a high-volume clinical skill.